Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Daiichi Sankyo logo

Daiichi Sankyo says meets targets in AF study

Edoxaban on course to add to next generation anticoagulants to replace warfarin

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

- PMLiVE

Boehringer to help promote genetic biomarker testing

Will support Bonnie J Addario Lung Cancer Foundation

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

- PMLiVE

Priority review for Lilly’s ramucirumab in gastric cancer

Update comes as company posts improved revenue results

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

Public unaware of main cause of liver cancer

Janssen-backed survey finds one in six people is aware of viral hepatitis role in the disease

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links